We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Saxenda

News List

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years prnasia
March 29, 2021
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years.
Novo Nordisk’s Saxenda bags NICE recommendation pharmatimes
November 05, 2020
Novo Nordisk’s obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK’s National Institute for Health and Care Excellence (NICE).
NICE recommends Novo Nordisk treatment for adults with obesity pharmaceutical-technology
November 02, 2020
National Institute for Health and Care Excellence (NICE) has recommended a new treatment option developed by Novo Nordisk for adults with obesity and non-diabetic hyperglycaemia.
Lured by high demand, Korean wholesaler smuggled Novo’s obesity drug Saxenda into China fiercepharma
November 15, 2018
Anti-obesity drug Saxenda has been one of Novo Nordisk’s key growth drivers lately—and apparently, a Korean wholesaler noticed. The pharmaceutical middleman allegedly smuggled the popular drug into China, where it’s not yet approved.